| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
General Counsel
1 company
Smith Jason Drew is a General Counsel at UroGen Pharma Ltd.. Recent SEC Form 4 filings include 0 buys and 17 sells.
Estimated insider holdings value: $1.9M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | URGN Urogen Pharma Ltd. | General Counsel | Sale+OE | 7,479 | $19.69 | $147,261.51 | -4.5% | +15.0% | - | |
| Sep 8, 2025 | URGN Urogen Pharma Ltd. | General Counsel | Sale+OE | 1,520 | $19.11 | $29,047.20 | -3.4% | +7.7% | - | |
| Jul 28, 2025 | URGN Urogen Pharma Ltd. | General Counsel | Sale+OE | 7,522 | $19.14 | $143,971.08 | -15.3% | +10.3% | - | |
| Jan 31, 2025 | URGN Urogen Pharma Ltd. | General Counsel | Sale+OE | 7,379 | $11.14 | $82,202.06 | -7.7% | +3.6% | +78.1% | |
| Sep 9, 2024 | URGN Urogen Pharma Ltd. | General Counsel | Sale+OE | 1,521 | $13.08 | $19,894.68 | -5.7% | -8.8% | +55.0% | |
| Jan 31, 2024 | URGN Urogen Pharma Ltd. | General Counsel | Sale+OE | 4,993 | $15.74 | $78,589.82 | -7.4% | -12.0% | -27.7% | |
| Aug 31, 2023 | URGN Urogen Pharma Ltd. | General Counsel | Sale+OE | 3,800 | $18.01 | $68,438.00 | -17.1% | -26.5% | -20.4% | |
| Jan 31, 2023 | URGN Urogen Pharma Ltd. | General Counsel | Sale+OE | 1,636 | $10.12 | $16,556.32 | -5.8% | +37.5% | +51.1% | |
| Aug 31, 2022 | URGN Urogen Pharma Ltd. | General Counsel | Sale+OE | 3,606 | $7.21 | $25,999.26 | -22.8% | +11.7% | +134.6% | |
| Jan 31, 2022 | URGN Urogen Pharma Ltd. | General Counsel | Sale+OE | 414 | $7.58 | $3,138.12 | -5.3% | -13.7% | +34.6% |